Bispecific antibody · Immune activation, directed at B7-H3 (CD276) (CD276) and CD3 (CD3E) · developed by MacroGenics
Obrindatamab (MGD009, orlotamab) is an Fc-bearing humanized dual-affinity re-targeting (DART) bispecific protein that binds B7-H3 on tumor cells and CD3 on T cells. By cross-linking these cells, it redirects endogenous T cells to kill B7-H3-expressing tumor cells. It is studied in solid tumors including mesothelioma, bladder cancer, melanoma, lung cancer, ovarian cancer, and prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03406949 | Phase 1 | Advanced Solid Tumors | Completed | MGNX |
| NCT02628535 | Phase 1 | Mesothelioma | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsBladder CancerBreast CancerClear Cell Renal Cell CarcinomaColon CancerMelanomaMesotheliomaNon Small Cell Lung CancerOvarian CancerPancreatic CancerProstate CancerSoft Tissue SarcomaSquamous Cell Carcinoma of the Head and NeckThyroid Cancer
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →